𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Missing data in trial-based cost-effectiveness analysis: the current state of play

✍ Scribed by Sian Marie Noble; William Hollingworth; Kate Tilling

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
559 KB
Volume
21
Category
Article
ISSN
1057-9230

No coin nor oath required. For personal study only.

✦ Synopsis

Randomised controlled trial (RCT)-based cost-effectiveness analyses, which are prone to missing data, are increasingly used in healthcare technology assessment. This has highlighted the need for appropriate methodological approaches to the handling of missing data. This paper reviews missing data methodology used in RCT-based cost-effectiveness analyses since 2003. Complete case analysis, which may lead to inappropriate conclusions, is still the most popular approach and its use has increased with time.

The degree of missing data in cost-effectiveness analyses was often poorly reported and the methodology was often unclear. Reporting of missing data sensitivity analyses would improve article transparency.

📜 SIMILAR VOLUMES

Assessing generalisability by location i
Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models
✍ Andrea Manca; Nigel Rice; Mark J. Sculpher; Andrew H. Briggs 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB 👁 1 views

## Abstract An Erratum has been published for this article in Health Economics 14(5) 2005, 486. Cost‐effectiveness analysis (CEA) in health care is increasingly conducted alongside multicentre and multinational randomised controlled clinical trials (RCTs). The increased use of stochastic CEA is de

Estimating mean QALYs in trial-based cos
Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility
✍ Andrea Manca; Neil Hawkins; Mark J. Sculpher 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB

## Abstract In trial‐based cost‐effectiveness analysis baseline mean utility values are invariably imbalanced between treatment arms. A patient's baseline utility is likely to be highly correlated with their quality‐adjusted life‐years (QALYs) over the follow‐up period, not least because it typical

Screening for cervical cancer in India:
Screening for cervical cancer in India: How much will it cost? A trial based analysis of the cost per case detected
✍ Rosa Legood; Alastair M. Gray; Cedric Mahé; Jane Wolstenholme; Kasturi Jayant; B 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 207 KB 👁 1 views

## Abstract The cost and cost effectiveness of screening previously unscreened women by VIA, cytology or HPV testing was investigated within a large cluster randomised trial involving 131,178 women in rural India. All resources involved in implementation, training, management, recruitment, screenin

The cost-effectiveness of community-base
The cost-effectiveness of community-based screening for oral cancer in high-risk males in the United States: A Markov decision analysis approach
✍ Raj C. Dedhia; Kenneth J. Smith; Jonas T. Johnson; Mark Roberts 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 192 KB 👁 1 views

## Abstract ## Objective: The 2004 US Preventative Services Task Force (USPSTF) guidelines do not recommend routinely screening adults for oral cancer given no proven mortality reduction. A large cluster‐randomized controlled screening trial in Kerala, India, in 2005, however, reported a significa